<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03894605</url>
  </required_header>
  <id_info>
    <org_study_id>DBTM</org_study_id>
    <nct_id>NCT03894605</nct_id>
  </id_info>
  <brief_title>Dermatological Abnormalities in Beta-thalassemia Major</brief_title>
  <official_title>Assessment ofDermatological Abnrmalities in Beta-thalassemia Major in Assiut University Pediatric Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to study the frequency and pattern of dermatological abnormalities in egyptian childern with
      beta thalassemia.relationof abnormalities to duration of disease and frequency of transfusion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      thalassemia refers to agroup of inherited disease characterized by decreased or absent
      synthesis of normal globin .skinvdisorders are usually neglected and frequently
      underdiagnosed among these patients.skin disease specially pruritus and xerosis are observed
      highly frequently in patients with beta-thalassemia.pityriasis alba is arelatively common
      skin disorder.the trophic skin changes and leg ulcers occurred after the age of 15 years
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2, 2020</start_date>
  <completion_date type="Anticipated">April 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with dermatological disorders due to iron overload Iron overload cause dermatological abnormalities</measure>
    <time_frame>one month</time_frame>
    <description>the number of patients who develop any dermatological disorder as a result of iron overload after frequent blood transfusion</description>
  </primary_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Beta-Thalassemia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>thalassemia</intervention_name>
    <description>thalassemic patient use chelator and thaladssemic patient with frequent blood transfusion</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patient examined by single dermatologist to record any dermatological abnormalities
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusio2n Criteria:

          -  clinical diagnosis of dermatological abnormalities in thalassemic patient. must be on
             chelator

        Exclusion Criteria:

          -  patient with other hemolytic anemia. childern with any abnormalities prior to the
             diagnosis of thalassemi
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alsayed khalil Abd elkareem, Professor</last_name>
    <phone>01060805170</phone>
    <email>Khalilsay@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mostafa Mohamed, Lecturer</last_name>
    <phone>01006244311</phone>
    <email>Mustafa-embaby@aun.edu.eg</email>
  </overall_contact_backup>
  <reference>
    <citation>Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010 Feb;12(2):61-76. doi: 10.1097/GIM.0b013e3181cd68ed. Review.</citation>
    <PMID>20098328</PMID>
  </reference>
  <results_reference>
    <citation>El-Dash H, Adel S. Cutaneous manifestations in Egyptian children with beta-thalassemia major: Relationship with serum ferritin, thyroid profile, and treatment modalities. Pediatr Dermatol. 2018 Sep;35(5):639-643. doi: 10.1111/pde.13570. Epub 2018 Jun 26.</citation>
    <PMID>29943859</PMID>
  </results_reference>
  <results_reference>
    <citation>Dogramaci AC, Savas N, Ozer B, Duran N. Skin diseases in patients with beta-thalassemia major. Int J Dermatol. 2009 Oct;48(10):1057-61.</citation>
    <PMID>19785086</PMID>
  </results_reference>
  <results_reference>
    <citation>CHANG PY, KUO CL, KHOO FY. The anatomic distribution of the lesions in pulmonary tuberculosis. Med Abstr. 1945 Oct;63A:237-43.</citation>
    <PMID>20997138</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Neveen Mamdoh Farag</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

